Archive
Imatinib in gastrointestinal stromal tumors (GIST): Northern Cancer Network Experience
F. Azribi, r. r. r. Razak, p. Dildey, j. Adam, j. Wilsdon and m. Verrill
Treatment of imatinib in unusable or metastatic gastrointestinal stromal tumors (GIST) has shifted the paradigm of treatment of this disease. Successful clinical trials of imatinib brought rapid regulatory approval and, in England and Wales, National Institute for Health and Clinical Excellence orientation (NICE) on the use of this technology.NICE detailed review of their recommended guidelines in clinical practice. Audit reflects that orientation and is designed to document the use of imatinib in routine clinical practice.
Methods: we conducted a retrospective audits of GIST patients treated with imatinib since 1 February 2002 to 31 March 2007. Information collected included patient demographics, the characteristics of the disease and details of the treatment administered, treatment response, toxicity and follow-up data.The primary goal was to record the disease control rate (DCR), defined as a lack of progress on computed tomography (CT) to 3 months. secondary end Points of the audits were devoid of overall survival and progression. These were compared with the results of published trials.
Results: were identified six thirty consecutive patients with diagnosed GIST treated with imatinib. The median age of patients was 70.1 years. During the analysis, patients were followed for a median of 41.6 months. In total, patients were treated to a median of 15,8 months.Treatment is generally well tolerated with a small percentage of patients experiencing the toxicity of grade 3/4. Control of the disease has been reported in 30 patients (DCR, 83.3%, 95% CI 67.2-93.6, intention to treat analysis).The median progression-free survival (PFS) in this cohort was 16.4 months (95% CI: 12.9-34,4);While the median overall survival (OS) was 39.7 months (95% CI: 22.8-56.5).
Conclusion: the data showed that treatment of patients with gist selected within the Guide NICE compares favorably to data previously published randomized studies of imatinib. registration of the note, the average age of this cohort is about 10 years earlier than the one reported in the trials. Imatinib was well tolerated with treatment related adverse events are acceptable.
Volume: 3 article number: 162 DOI: 10.3332/ecancer. 2010.162 received: 10/10/2009 published: 14/12/2009
To view this article in its entirety, you must first sign in or register.
The development of an infrastructure of European network for research on cancer: vision, architecture and services
M. Rueping Tsiknakis, s., l. Martin, s. Sfakianakis, r. Sengstag Bucur, t., m. Pucaski Brochhausen, j., b. Graf
Life sciences are currently in the middle of a informational revolution. The nature and amount of information available now open directions of research that once were in the realm of science fiction.During this revolution statement, data collection capabilities have significantly exceeded the techniques of data analysis. integrating data between heterogeneous data sources and aggregation of data across different aspects of spectrum biomedical, therefore, is at the heart of current biomedical and pharmaceutical R&D.
This paper reports on the results of the integrated project ACGT original focusing on designing and developing a European biomedical grid infrastructure in support of multicentric, post genomic clinical cancer.Post-Genomic clinical trials (CTs) use clinical data and multilevel and advanced genomic analysis tools and computational view to verify the assumptions made in an attempt to identify the reasons for a disease molecular and stratification of patients in terms of treatment.
The document provides a presentation of the needs of users involved in CTs post-genomics and presents indicative scenarios that drive the requirements of the design phase of the project. Subsequently, presents the initial architecture specified by the project and its services are classified and discussed. a range of these key services, including the ontology master on cancer that is located in the heart of the architecture of integration of the project, are presented. Special efforts were taken to describe the technological and methodological framework of the project, allowing the creation of an infrastructure legally compliant and naive.
Finally, a brief discussion of the next job is included and describes the potential involvement of the cancer research community in the further development or the use of infrastructure.
Volume: 1 article number: 56 DOI: 10.3332/ecms. 2007.56 received: 15/07/2007 published: 21/09/2007
To view this article in its entirety, you must first sign in or register.
cancer3 